In our previous trials with fludarabine treatment in patients of granulocyte colony-stimulating factor (G-CSF) following with CLL, we found a significantly higher incidence of severe fludarabine would reduce the incidences of myelosuppression infections, such as sepsis or pneumonia, in pretreated patients and infections. Twenty-five previously treated patients with Rai and in those with advanced Rai stage disease. 13 The incidence 
Introduction

Patients and methods
The major cause of morbidity and mortality in patients with Between May 1992 and June 1994, 25 patients with CLL were chronic lymphocytic leukemia (CLL) is infection. 1 Predisentered on study after informed consent was obtained accordposition to infection is mediated through various abnormaliing to institutional guidelines. All patients underwent a ties. T cell dysfunction manifested by abnormal responses to workup that included medical history and physical examinstimulating factors such as phytohemagglutinin and interleuation; complete blood counts, differential, and platelet counts; kin-2 has been found in patients with CLL. 2, 3 The clinical corsequential multiple analysis-12 including liver and renal funcrelate of this abnormality may be the decreased responsivetion studies; and bone marrow aspiration and biopsy. Entry ness noted on skin testing, with anergy frequently detected in criteria required a confirmation of the diagnosis with a monopatients who have advanced stage disease. 4 Hypogammaglobtypic expansion of lymphoid cells у5 × 10 3 /l morphologiulinemia also often occurs in patients with CLL, especially in cally consistent with CLL (small lymphocytes). Patients had to those who have long-standing disease. 5, 6 This occurs preferenhave advanced Rai stage disease (III-IV) as evidenced by a tially in the subtypes of IgG3 and IgG4. 7 This deficiency of hemoglobin level Ͻ11.0 g/dl and/or platelet count IgG4 may explain the high incidence of respiratory infections Ͻ100 000/l and normal renal (creatinine Ͻ2.0 mg%) and in patients with CLL.
8,9 Also of note is that IgG3 is important hepatic (bilirubin Ͻ2.0 mg%) functions. in protection against herpes infections, another common problem in CLL patients.
9,10 Neutropenia, a well-known factor predisposing to infection, may occur in the face of extensive bone Treatment regimen and response criteria marrow involvement and is worsened by myelosuppressive chemotherapy.
11,12 Finally, immune suppression that causes Therapy consisted of fludarabine 30 mg/m 2 intravenously for decreasing CD4 T cell counts occurs frequently with nucleo-30 min each day for 5 days. Courses were repeated every 4 side analogue therapy. [13] [14] [15] weeks. G-CSF was given at a dose of 5 g/kg subcutaneously beginning on a day 6 (the day after the last fludarabine dose) and continued until an absolute granulocyte count (AGC) of 10 000/l was reached. If the AGC dropped to Ͻ5000/l the The median number of courses of fludarabine and G-CSF monocytogenes sepsis or Pneumocystis carinii pneumonia given was three (range, 1-9). Disease in eight patients (32%) that were seen only in patients given the combination therresponded to therapy with fludarabine and G-CSF. Responders apy. 13 Response criteria for the historical control group were received a median of five courses. Three patients had a PR the same as those described above.
and five patients entered CR, although in four of those cases residual lymphoid nodules were found on bone marrow biopsy. The response rate in patients who had previously received fludarabine was 25% (three of 12) vs 38% (five of Statistical consideration 13) in patients not previously exposed to fludarabine therapy (P = 0.47). CR rates were 8% (one of 12) in patients previously Comparisons between events were evaluated by the 2 test. treated with fludarabine vs 30% (four of 13) in patients who Distributions of survival and time to disease progression were had not previously received fludarabine (P = 0.16). estimated by the method of Kaplan and Meier. 21 Survival Historical control patients received a median of four intervals were measured from the first day of chemotherapy courses of fludarabine; responders received a median of six to death, and deaths from all causes were included. Time of courses. The overall response rate in those 145 patients who disease progression was measured from the first day of chemoreceived 5 days of fludarabine with or without prednisone was therapy to the first detection of recurrence.
41%, with a CR rate of 23% (67% with residual biopsy nodules). All patients in the historical group had received fludarabine for the first time. Response rates of the historical Results control population were not significantly different when compared with those of the current study.
Patient characteristics
The median time to disease progression was 25 months in the current study patients and 20 months in the historical control group (Figure 1 , P = 0.65). Three patients died during the Characteristics of study patients and historical controls are shown in Table 1 . The median age of the G-CSF-treated first course of therapy. Of all patients who could be evaluated for a response, three patients had no record of the extent of patients was 67 years (range, 42-83 years), and 13 (52%) were women. The median time from diagnosis was 64 months lymphadenopathy after the chemotherapy. Of the remaining 19 patients, 17 (89%) had at least a PR in their lymphadenopa-(range, 3-135 months) and the median number of prior regimens was one (range, 1-7). Twelve (48%) patients had prethy. In most cases, failure of therapy to produce a response was related to persistent thrombocytopenia. The median surviously received fludarabine. Disease in two (17%) of those 12 patients was refractory to the prior fludarabine. Other therapy vival was 22 months in the current study and 12 months in the historical controls ( Figure 2 , P = 0.43). Nine patients are included chlorambucil with or without prednisone in 12 patients, cyclophosphamide, vincristine and prednisone still alive. (COP) in two patients, cyclophosphamide, doxorubicin, vincristine and prednisone in three patients, interferon alpha in three patients, and cytosine arabinoside and cis-platinum Myelosuppression in one patient. Disease in 16% of patients was refractory to alkylating agents. Twenty-two (88%) patients had Rai stage IV Twenty patients started chemotherapy with an AGC Ͼ1000/l. During the first course of therapy seven (35%) disease at the start of therapy. Seven (41%) of 17 assessable patients had hypogammaglobulinemia (IgG Ͻ650 g/dl).
patients had a nadir AGC Ͻ1000/l; only two (10%) patients Table 2 Comparison of granulocyte nadirs of study and historical control patients
AGC value (per l)
Percent with event P value
Fludarabine Historical + G-CSF controls
patients are shown in Table 2 . Regardless of whether a nadir AGC Ͻ1000/l or 500/l is considered, in almost every instance, there is a statistically significant greater degree of granulocytopenia in the historical group. In nine (45%) of 20 patients who started fludarabine and G-CSF therapy with normal granulocyte counts, AGCs decreased to Ͻ1000/l at some time during the first three cycles. This is in comparison to 75 (79%) of 95 historical patients treated with fludarabine without growth factor (P = 0.002). The degree of myelosuppression at the beginning of therapy was comparable because 25% of study patients began therapy with an AGC Ͻ1000/l vs such an AGC in 28% of historical control patients.
Figure 2
Time to progression of historical control and G-CSFtreated patients.
Course intervals
The median number of days of the first, second and third courses in the study group were 30, 28 and 29. This compared had a nadir AGC Ͻ500/l. All patients who received a second with 29, 33 and 29 in the historical control group. However, course of fludarabine had an AGC Ͼ1000/l at the start of a marked difference is seen when the incidences of prolonged course 2, including three of the five patients who began therdelays in treatment are compared (Table 3) . Fifty percent of apy with an AGC Ͻ1000/l. Two of those five patients did historical control patients had at least one course delayed by not receive a second course because one patient died and Ͼ35 days compared with only 20% of the G-CSF-treated disease progressed in the other. Of the 19 patients who patients (P = 0.005). Delays Ͼ42 or 49 days were seen in 29 received a second course of therapy, only two (11%) had a and 23% of control patients, compared with 12% of study nadir AGC Ͻ1000/l; no patient had a nadir AGC Ͻ500/l. patients for each time period. Fifteen patients received a third course of fludarabine and G-CSF. There were no data regarding granulocyte counts in two patients. All other patients had a starting AGC Ͼ1000/l. AGC reached a nadir of Ͻ1000/l in four (27%) patients and Table 3 Comparison of therapy delays between study and histori-Ͻ500/l in one (7%). Combined data for the first three cal control patients courses showed that nine (45%) of 20 assessable patients had an episode of granulocytopenia Ͻ1000/l. Only three (15%)
Course days Percent of patients P value patients had a nadir AGC Ͻ500/l at any time during the first three cycles of therapy. A total of 27 courses were given AGCs for the first three courses or at any time during the first three courses for study patients and historical control Infections or febrile episodes serious infections vs 54% of previously treated patients with Rai stage III-IV disease. These were similar for patients treated with single-agent fludarabine, with the only difference being Severe infections, defined as pneumonia or bacteremia, were seen in six (24%) patients treated with fludarabine and G-CSF the development of Listeria monocytogenes sepsis or Pneumocystis carinii pneumonia in 13 patients treated with combi- (Table 4 ). There were four (16%) episodes of sepsis (Pseudomonas, Escherichia coli, Listeria monocytogenes and nation therapy. Twenty-one (88%) of 24 historical controls who died within 3 months of beginning fludarabine therapy unspecified gram-negative rod) and two (8%) episodes of pneumonia (culture negative) in all 83 courses. Three epidied with complications of pneumonia and/or sepsis. Myelosuppression was more common in patients with advanced dissodes occurred on course 1, one on course 2, and two on course 3. The patient that developed Listeria sepsis also ease with neutropenia occurring in 79% of patients. Although cellular immunity may be important in the prevention of atypireceived high-dose steroids for hemolytic anemia. All three episodes of severe infection that occurred on the first course cal and viral infections, granulocytopenia may be crucial to the development of bacterial infections and pneumonia, as resulted in the deaths of the patients. Two of these three patients were Ͼ70 years old vs seven of 22 patients who surhas been demonstrated in other patients with chemotherapyinduced granulocytopenia. vived the induction course (P = 0.24). No severe infections occurred in the 27 cycles given beyond course three. In con-
The current study shows that the use of G-CSF resulted in a statistically significant decrease in pneumonia. Patients who trast, 19% of historical control patients experienced sepsis and 37% had pneumonia at some time during fludarabine therapy. received G-CSF had an 8% incidence of pneumonia vs a 37% incidence in historical control patients. Previously described The 8% incidence of pneumonia in the G-CSF-treated patients is a significant decline from that seen in historical patients.
risk factors for infection in patients with CLL included age, disease stage, prior therapy, hypogammaglobulinemia and Febrile episodes (without microbiologic infection or localization) occurred in five (20%) patients; one patient had neutropenia. 22 G-CSF-treated patients tended to be older and had more advanced disease than did historical controls. Howtwo febrile episodes and another had three episodes for a total of eight episodes (10%) of 83 courses. Minor infections ever, the control group had been more extensively pretreated and had a higher incidence of hypogammaglobulinemia. The (cellulitis, bronchitis, upper respiratory infection and urinary tract infection) occurred in four (16%) patients or in 5% of incidence of pneumonia in the historical group did not vary because of Rai stage (III or IV), hypogammaglobulinemia, or the total courses. There was no significant difference in the incidence of these infections between G-CSF-treated patients number of prior regimens. Pneumonia occurred in 42% of patients with Rai stage III disease vs 30% of patients with Rai and historical controls. Reactivation of herpes simplex type I or II occurred in six (24%) patients or in 7% of courses. No stage IV disease (P = 0.13), and in 34% of patients with hypogammaglobulinemia vs 42% of those with normal gammaherpes zoster infection was observed. There was no siginificant difference in the incidence of any type of infection among globulin levels (P = 0.38). Patients who had only one prior regimen had a 33% incidence of pneumonia vs 40% of patients who had or had not received prior fludarabine. patients treated after two prior regimens and 34% of patients exposed to three or more prior regimens (P = 0.82). There was a trend for a higher incidence of pneumonia in patients older Discussion than 60 years old, 42 vs 29% in patients younger than 60 (P = 0.11). However, this would favor the data in G-CSFNuceloside analogue therapy has resulted in a major advance in the treatment of indolent lymphoid malignancies. Extratreated patients because the study group had more patients who were older than 60 years than did the historical group medullary toxic effects were minimal and complications were due to myelosuppression and infection. Infections are a parti-(72 vs 52%). Comparing courses, during which pneumonia developed vs cular problem in CLL because the disease can cause impaired humoral and cellular immunity and hypogammaglobulinethose during which it did not among historical control patients shows that the only significant factor was neutropenia. Fourmia. Myelosuppression resulting from inadequate bone marrow function, or chemotherapy, contributes to the significant teen percent of courses for which the nadir AGC was Ͻ1000/l were complicated by pneumonia vs 9% of other incidence of infections seen in patients with advanced disease.
courses (P = 0.19). Severe neutropenia was more significant, with pneumonia occurring in 16% of courses for which the We previously showed a relationship between the development of serious infections (bacteriemia or pneumonia) and nadir AGC was Ͻ500/l vs 8% of courses for which the AGC was Ͼ500/l (P = 0.009). both advanced-stage disease and prior therapy.
13 Twelve percent of previously untreated patients with Rai stage 0-II disNeutropenia would be expected to have the strongest impact on the incidence of bacterial and fungal infections. ease who received fludarabine and prednisone developed Table 4 Comparison of febrile episodes or infections between study and historical control patients 
